Ayble Health raises $16M Series A to scale AI digestive + autoimmune care

Ayble Health said it closed a $16 million oversubscribed Series A led by Neon, with Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice, and others participating. The company says total capital raised now exceeds $27 million and will fund deeper AI precision-care tools plus expansion from gastrointestinal care into autoimmune conditions.

HEALTH desk — same-day disclosed Series A for an AI-enabled virtual GI clinic that says it already covers tens of millions of insured Americans and is pushing the same model into autoimmune disease.

Participating investors named on the same wire, still company: Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice, and several individual strategic investors. The company says the round brings total capital raised to over $27 million. File the $16 million figure, the Neon lead, those named participants, and the over-$27 million cumulative line as Ayble’s. This desk is not inventing a valuation, a prior-round split, an ownership percentage, or a check size. None was printed.

Use of funds, as the same wire has it: advance Ayble’s proprietary AI+clinician precision care model; deepen data-driven personalization for patient engagement, enrollment, and care delivery; and expand beyond its core gastrointestinal — GI, meaning digestive — footprint into adjacent complex conditions, starting with autoimmune disease. File that spend plan as Ayble’s. This desk did not sit in a board meeting.

Coverage claim, still company: Ayble says it is now in-network with most commercial health plans and covers 80-plus million Americans through payer, employer, and health-system partnerships. File the in-network / 80-plus-million line as Ayble’s. This desk did not count covered lives or audit a payer contract.

Clinical claims, company-attributed — do not independently verify: the company says its model is backed by 16-plus peer-reviewed clinical studies across major GI populations, more than any other virtual digestive-health company on its own wording. Across its book of business, Ayble says it achieves an average 47% improvement in GI symptoms, typically within four weeks and sustained for at least a year. An independent analysis from the Peterson Health Technology Institute, the company says, recognized Ayble’s clinical team as the broadest in the GI category. File the 16-plus studies, the 47% / four-week / one-year lines, and the Peterson “broadest team” cite as Ayble’s. This desk did not rerun the studies, sit with Peterson, or inventory every virtual GI clinic.

Product framing, still company: Ayble calls itself an AI-enabled virtual multidisciplinary GI clinic — remote specialty care with a software layer, not a hospital building. The about box says patients get unlimited access to a specialized multidisciplinary care team, a suite of AI-powered precision tools, and curated wellness support for chronic digestive and autoimmune conditions. The wire names the team mix as GI-trained providers, registered dietitians, behavioral-health specialists, clinical pharmacists, health coaches, and care coordinators, paired with proprietary technology. File that unlimited-access / AI-tools / team-mix picture as Ayble’s. This desk did not enroll a patient or open the app. This is a care-clinic and software funding story. The Sep 16 wire does not claim FDA device clearance. This desk is not inventing one.

Named company voice: Sam Jactel, founder and CEO of Ayble Health. The company and Jactel say he built Ayble because he is an inflammatory bowel disease — IBD — patient, and that the new capital lets the company deepen AI precision-care tools and extend the same multidisciplinary model into autoimmune care. File the name, title, the IBD-patient line, and that deepen-and-extend plan as his, via Ayble. His other quotes are color only and stay in Sources.

Plain English for the rest of the card: Series A = growth venture round after seed. GI = gastrointestinal / digestive. IBD = inflammatory bowel disease, a chronic gut condition such as Crohn’s or ulcerative colitis. virtual clinic = a remote specialty care team plus software, not a hospital building. autoimmune = conditions where the immune system attacks the body. in-network = the clinic is contracted with a health plan so a visit can count as covered care. oversubscribed = more investors wanted in than the company took.

PRIMARY here: Ayble Health’s 16 Sep 2026 PR Newswire company release — Tier A PRIMARY company source, the original record. The ayblehealth.com company home is product-home context, not a second originating newsroom. The $16 million oversubscribed Series A, the Neon lead, Unum Ventures / Upfront Ventures / M13 / Cleveland Clinic Ventures / DigiTx / Accomplice / individual strategic investors, the over-$27 million cumulative capital line, the AI+clinician precision-care / GI-to-autoimmune use of funds, the in-network / 80-plus-million coverage claim, the 16-plus studies / 47% / four-week / one-year outcome lines, the Peterson Health Technology Institute team-breadth cite, the unlimited multidisciplinary access plus AI precision-tools product frame, and the Jactel title and IBD-patient line are company-attributed. Coverage counts, clinical-study counts, outcome percentages, and the Peterson cite stay company-attributed — not independently audited here. NOT claimed: a valuation, prior-round splits, FDA device clearance, independently verified outcome rates or covered-life counts, that this desk reviewed a term sheet or enrolled a patient, a stock tip, or investment advice. Distinct from the already-filed ferry-health-9m, kells-ai-dental-scan-hsa, evvy-40m-series-b, kairon-health-5m, tandem-health-100m-series-b, ge-careintellect-operations, and nara-health-14m.